Neuroblastoma patient-derived orthotopic xenografts reflect the microenvironmental hallmarks of aggressive patient tumours

Cancer Letters

Volumn 375, Issue 2, 2016, Pages 384-389

  Braekeveldt, Noémie ^a   Wigerup, Caroline ^a   Tadeo, Irene ^b   Beckman, Siv ^a   Sandén, Caroline ^c   Jönsson, Jimmie ^c   Erjefält, Jonas S ^c   Berbegall, Ana P ^c   Börjesson, Anna ^d   Backman, Torbjörn ^d   Øra, Ingrid ^a   Navarro, Samuel ^c   Noguera, Rosa ^c   Gisselsson, David ^a,e   Påhlman, Sven ^a   Bexell, Daniel ^a  

^a LUND UNIVERSITY   (Sweden)

^b UNIVERSITY OF VALENCIA   (Spain)

^c LUND UNIVERSITY   (Sweden)

^d LUND UNIVERSITY HOSPITAL   (Sweden)

^e University and Regional Laboratories ^*  (Sweden)

Author keywords

Metastasis; Neuroblastoma; Paediatric cancer; Patient derived xenograft (PDX); Tumour microenvironment; Tumour stroma

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; CHROMOGRANIN A; PROTEIN S100B; SYNAPTOPHYSIN; TYROSINE 3 MONOOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CELL VIABILITY; CONTROLLED STUDY; COPY NUMBER VARIATION; FEMALE; GENOTYPE; HUMAN; HUMAN TISSUE; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; MALE; MORPHOLOGY; MOUSE; NEUROBLASTOMA; NONHUMAN; PATIENT DERIVED ORTHOTOPIC XENOGRAFT; PERICYTE; PHENOTYPE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION; TUMOR XENOGRAFT; ANIMAL; BLOOD VESSEL; DISEASE MODEL; DRUG SCREENING; GENETICS; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY;

ANIMALS; BLOOD VESSELS; DISEASE MODELS, ANIMAL; GENOTYPE; HUMANS; MICE; NEOVASCULARIZATION, PATHOLOGIC; NEUROBLASTOMA; POLYMORPHISM, SINGLE NUCLEOTIDE; TUMOR MICROENVIRONMENT; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84961789680     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2016.02.046     Document Type: Article

References (37)

1. Kola I., Landis J. Can the pharmaceutical industry reduce attrition rates?. Nat. Rev. Drug Discov 2004, 3:711-715.
2. Ocana A., Pandiella A., Siu L.L., Tannock I.F. Preclinical development of molecular-targeted agents for cancer. Nat. Rev. Clin. Oncol 2011, 8:200-209.
3. Hidalgo M., Amant F., Biankin A.V., Budinska E., Byrne A.T., Caldas C., et al. Patient-derived xenograft models: an emerging platform for translational cancer research. Cancer Discov 2014, 4:998-1013.
4. Tentler J.J., Tan A.C., Weekes C.D., Jimeno A., Leong S., Pitts T.M., et al. Patient-derived tumour xenografts as models for oncology drug development. Nat. Rev. Clin. Oncol 2012, 9:338-350.
5. Siolas D., Hannon G.J. Patient-derived tumor xenografts: transforming clinical samples into mouse models. Cancer Res 2013, 73:5315-5319.
6. Rosfjord E., Lucas J., Li G., Gerber H.P. Advances in patient-derived tumor xenografts: from target identification to predicting clinical response rates in oncology. Biochem. Pharmacol 2014, 91:135-143.
7. Cheung N.K., Dyer M.A. Neuroblastoma: developmental biology, cancer genomics and immunotherapy. Nat. Rev. Cancer 2013, 13:397-411.
8. Maris J.M., Hogarty M.D., Bagatell R., Cohn S.L. Neuroblastoma. Lancet 2007, 369:2106-2120.
9. Braekeveldt N., Wigerup C., Gisselsson D., Mohlin S., Merselius M., Beckman S., et al. Neuroblastoma patient-derived orthotopic xenografts retain metastatic patterns and geno- and phenotypes of patient tumours. Int. J. Cancer 2015, 136:E252-E261.
10. Borriello L., Seeger R.C., Asgharzadeh S., DeClerck Y.A. More than the genes, the tumor microenvironment in neuroblastoma. Cancer Lett 2015, 10.1016/j.canlet.2015.11.017.
11. Klemm F., Joyce J.A. Microenvironmental regulation of therapeutic response in cancer. Trends Cell Biol 2015, 25:198-213.
12. Barker H.E., Paget J.T., Khan A.A., Harrington K.J. The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence. Nat. Rev. Cancer 2015, 15:409-425.
13. Charles N., Ozawa T., Squatrito M., Bleau A.M., Brennan C.W., Hambardzumyan D., et al. Perivascular nitric oxide activates notch signaling and promotes stem-like character in PDGF-induced glioma cells. Cell Stem Cell 2010, 6:141-152.
14. Vermeulen L., De Sousa E.M.F., van der Heijden M., Cameron K., de Jong J.H., Borovski T., et al. Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nat. Cell Biol 2010, 12:468-476.
15. Pietras K., Ostman A. Hallmarks of cancer: interactions with the tumor stroma. Exp. Cell Res 2010, 316:1324-1331.
16. Meitar D., Crawford S.E., Rademaker A.W., Cohn S.L. Tumor angiogenesis correlates with metastatic disease, N-myc amplification, and poor outcome in human neuroblastoma. J. Clin. Oncol 1996, 14:405-414.
17. Ribatti D., Nico B., Cimpean A.M., Raica M. Podoplanin and LYVE-1 expression in lymphatic vessels of human neuroblastoma. J. Neurooncol 2010, 100:151-152.
18. Asgharzadeh S., Salo J.A., Ji L., Oberthuer A., Fischer M., Berthold F., et al. Clinical significance of tumor-associated inflammatory cells in metastatic neuroblastoma. J. Clin. Oncol 2012, 30:3525-3532.
19. Vakkila J., Jaffe R., Michelow M., Lotze M.T. Pediatric cancers are infiltrated predominantly by macrophages and contain a paucity of dendritic cells: a major nosologic difference with adult tumors. Clin. Cancer Res 2006, 12:2049-2054.
20. Zeine R., Salwen H.R., Peddinti R., Tian Y., Guerrero L., Yang Q., et al. Presence of cancer-associated fibroblasts inversely correlates with Schwannian stroma in neuroblastoma tumors. Mod. Pathol 2009, 22:950-958.
21. Shimada H., Ambros I.M., Dehner L.P., Hata J., Joshi V.V., Roald B., et al. The International Neuroblastoma Pathology Classification (the Shimada system). Cancer 1999, 86:364-372.
22. Shimada H., Chatten J., Newton W.A., Sachs N., Hamoudi A.B., Chiba T., et al. Histopathologic prognostic factors in neuroblastic tumors: definition of subtypes of ganglioneuroblastoma and an age-linked classification of neuroblastomas. J. Natl. Cancer Inst 1984, 73:405-416.
23. Berbegall A.P., Villamon E., Tadeo I., Martinsson T., Canete A., Castel V., et al. Neuroblastoma after childhood: prognostic relevance of segmental chromosome aberrations, ATRX protein status, and immune cell infiltration. Neoplasia 2014, 16:471-480.
24. Tadeo I., Piqueras M., Montaner D., Villamon E., Berbegall A.P., Canete A., et al. Quantitative modeling of clinical, cellular, and extracellular matrix variables suggest prognostic indicators in cancer: a model in neuroblastoma. Pediatr. Res 2014, 75:302-314.
25. Jackson D.G. The lymphatics revisited: new perspectives from the hyaluronan receptor LYVE-1. Trends Cardiovasc. Med 2003, 13:1-7.
26. Ramani P., Dungwa J.V., May M.T. LYVE-1 upregulation and lymphatic invasion correlate with adverse prognostic factors and lymph node metastasis in neuroblastoma. Virchows Arch 2012, 460:183-191.
27. Bossen C., Ingold K., Tardivel A., Bodmer J.L., Gaide O., Hertig S., et al. Interactions of tumor necrosis factor (TNF) and TNF receptor family members in the mouse and human. J. Biol. Chem 2006, 281:13964-13971.
28. DeRose Y.S., Wang G., Lin Y.C., Bernard P.S., Buys S.S., Ebbert M.T., et al. Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes. Nat. Med 2011, 17:1514-1520.
29. Gray D.R., Huss W.J., Yau J.M., Durham L.E., Werdin E.S., Funkhouser W.K., et al. Short-term human prostate primary xenografts: an in vivo model of human prostate cancer vasculature and angiogenesis. Cancer Res 2004, 64:1712-1721.
30. Bankert R.B., Balu-Iyer S.V., Odunsi K., Shultz L.D., Kelleher R.J., Barnas J.L., et al. Humanized mouse model of ovarian cancer recapitulates patient solid tumor progression, ascites formation, and metastasis. PLoS ONE 2011, 6:e24420.
31. Simpson-Abelson M.R., Sonnenberg G.F., Takita H., Yokota S.J., Conway T.F., Kelleher R.J., et al. Long-term engraftment and expansion of tumor-derived memory T cells following the implantation of non-disrupted pieces of human lung tumor into NOD-scid IL2Rgamma(null) mice. J. Immunol 2008, 180:7009-7018.
32. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
33. Karaman S., Detmar M. Mechanisms of lymphatic metastasis. J. Clin. Invest 2014, 124:922-928.
34. Wege A.K., Ernst W., Eckl J., Frankenberger B., Vollmann-Zwerenz A., Mannel D.N., et al. Humanized tumor mice - a new model to study and manipulate the immune response in advanced cancer therapy. Int. J. Cancer 2011, 129:2194-2206.
35. Liu D., Song L., Wei J., Courtney A.N., Gao X., Marinova E., et al. IL-15 protects NKT cells from inhibition by tumor-associated macrophages and enhances antimetastatic activity. J. Clin. Invest 2012, 122:2221-2233.
36. Rongvaux A., Willinger T., Martinek J., Strowig T., Gearty S.V., Teichmann L.L., et al. Development and function of human innate immune cells in a humanized mouse model. Nat. Biotechnol 2014, 32:364-372.
37. Morton J.J., Bird G., Keysar S.B., Astling D.P., Lyons T.R., Anderson R.T., et al. XactMice: humanizing mouse bone marrow enables microenvironment reconstitution in a patient-derived xenograft model of head and neck cancer. Oncogene 2016, 35:290-300.